Biocon Ltd

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 394.6, up 0.99% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 25504.3. The Sensex is at 82333.07, up 0.13%. Biocon Ltd has gained around 8.04% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 5.55% in last one month and is currently quoting at 22632.05, up 1.62% on the day. The volume in the stock stood at 19.62 lakh shares today, compared to the daily average of 31.82 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 397.7, up 1.21% on the day. Biocon Ltd is up 26.54% in last one year as compared to a 13.13% jump in NIFTY and a 13.84% jump in the Nifty Pharma index.The PE of the stock is 325.29 based on TTM earnings ending December 25.Powered by Capital Market - Live

Biocon has received approval from the U.S. FDA, for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda'). Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity. GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption. Powered by Capital Market - Live

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity. GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption. According to IQVIA MAT December 2025 the total addressable market opportunity for GLP-1 in weight loss in the U.S. was US $127 million. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'This timely approval of gSaxenda in the United States marks a defining milestone for Biocon, validating our scientific depth, our vertically integrated development and manufacturing platform, and our ability to bring complex drug products to markets around the world. GLP-1 therapies represent a significant growth driver for the company, with the U.S. being an important market in this strategy.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25. The scrip rose 0.35% to currently trade at Rs 391.70 on the BSE. Powered by Capital Market - Live

Net profit of Biocon rose 472.91% to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4123.00 crore in the quarter ended December 2025 as against Rs 3773.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales4123.003773.00 9 OPM %20.2219.93 - PBDT740.90563.20 32 PBT225.60137.80 64 NP143.8025.10 473 Powered by Capital Market - Live

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 373.85, up 0.42% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 25738.7. The Sensex is at 83674.2, down 0.08%. Biocon Ltd has dropped around 4.47% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 2.45% in last one month and is currently quoting at 22200.25, down 0.07% on the day. The volume in the stock stood at 7.52 lakh shares today, compared to the daily average of 33.42 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 375.75, up 0.51% on the day. Biocon Ltd is down 4.2% in last one year as compared to a 8.62% gain in NIFTY and a 1.45% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending September 25.Powered by Capital Market - Live

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 383.95, up 1.31% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25755.6. The Sensex is at 83702.57, up 0.38%. Biocon Ltd has slipped around 0.56% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.33% in last one month and is currently quoting at 22505.4, down 0.86% on the day. The volume in the stock stood at 17.89 lakh shares today, compared to the daily average of 26.3 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 384.45, up 1.33% on the day. Biocon Ltd is down 2.48% in last one year as compared to a 11% jump in NIFTY and a 1.13% jump in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending September 25.Powered by Capital Market - Live

Biocon announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore (~USD 460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per equity share (including a premium of Rs 363.35 per equity share). The QIP, which opened on 12 January 2026, and closed on 14 January 2026, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in Biocon's growth prospects. The proceeds from the QIP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics, including repayment of debt availed in this regard. Biocon recently announced that its Board of Directors had approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon Biologics a wholly owned subsidiary of the Company.Powered by Capital Market - Live

Biocon will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live

Securities in F&O Ban: Shares of Steel Authority of India (SAIL) and Sammaan Capital are banned from F&O trading on 7 January 2026. Stocks to Watch: Biocon's subsidiary, Biocon Biologics will introduce three new oncology biosimilars at a US event. Titan Company's consumer business registered a growth of 40% YoY in Q3FY26. A total of 56 stores (net) were added during the quarter expanding Titan's combined retail network presence to 3,433 stores. Lodha Developers' pre sales jumped 25% to Rs 56,200 crore in Q3 FY26 compared with Rs 45,100 crore in Q3 FY25. Collections declined 17% YoY to Rs 35,600 crore in Q3 FY26. Jubilant Foodworks' consolidated revenue stood at Rs 2,438.7 crore in Q3 FY26, up 13.4% YoY. Domino's recorded a Like-For-Like (LFL) growth of 5%. Senco Gold reported a 51% revenue growth in Q3 FY26, driven by robust performances across its businesses. The retail business reported around 49% growth while SSSG growth stood at 39%. Godrej Consumer Products' standalone business is well positioned to deliver double-digit revenue growth for the quarter, underpinned by close to double-digit underlying volume growth (UVG), albeit on a supportive comparator. Personal Care is expected to record mid-single-digit value growth, driven by a marked recovery in the soaps category.Powered by Capital Market - Live

Biocon Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 399.7, up 0.1% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 26175.65. The Sensex is at 85535.57, down 0.04%. Biocon Ltd has risen around 1.13% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 1.82% in last one month and is currently quoting at 22927.9, down 0.11% on the day. The volume in the stock stood at 12.75 lakh shares today, compared to the daily average of 34.28 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 400.5, up 0.18% on the day. Biocon Ltd is up 16.02% in last one year as compared to a 10.32% spurt in NIFTY and a 1.52% spurt in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending September 25.Powered by Capital Market - Live